Auri Knowledge

WHO WE ARE

Discover how safely we lead our customers through early stage product development research and fully customized in-vivo and in-vitro studies. View more

SUPPORTING SUCCESS

See how we monitor and support the planning and set-up of studies at an early stage. View more

SOLVING PROBLEMS

Experience how we always strive for the best solution, generating tailor-made products and services in drug research and testing. View more

EXPANDING THE RADIUS

Find out, why we consider ourselves as our clients extended arm in drug development, fast, efficient and interdisciplinary. View more

TURNKEY SOLUTIONS

Discover our turnkey preclinical package solutions being entirely customized to customer needs. View more

CLEARING THE PATH

Feel the dedication and passion for our customers.
Discover how our advisory team stands at their side on the way to future success. View more

SPEAKING SCIENCE

Explore our culture of direct communication in which scientist talk with scientists, from the first contact until the final document. View more

Aurigon News

18|05|11//Meet us and bioPmed

Meet us and bioPmed cluster members at Bioindustry Park Silvano Fumero! We will hold a workshop on “Utilization of…

View more

18|04|26// CE Bioforum in Lodz

Meet us at CE Bioforum in Lodz on 23-24 May! CE Bioforum is the biggest and the most important…

View more

18|04|27//MIXii Biomed

Meet us at the MIXii Biomed in Tel Aviv! As the leading event of Israel’s life sciences industry, MIXiii-BIOMED…

View more

Science NEWS

17|10|02//Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity

Source: Nature. By: Nobuyuki Tanaka, Shigeaki Kanatani [...] Peter Uhlén.  Intratumoral heterogeneity is a critical factor when diagnosing and treating patients with…

View more

17|10|02//Researchers unravel patterns of cancer heterogeneity

Source: European Biotechnology Life Science and Industry Magazine, By: TG. Up to recently, it was not possible for academic researchers…

View more

17|06|08//Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s

Source: Alzheimer's News Today. By: Iqra F. Mumal. Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained…

View more
Auri Knowledge